Physician profile
Mark E Lassise
NPI 1023002508
$7,779.33
in general payments reported to CMS, 2019-2025
20 companies · $998 in 2025
The $998 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,232 · 2021: $930 · 2022: $1,450 · 2023: $929 · 2024: $955 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,261.22 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,152.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $913.70 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $878.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $710.65 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $651.63 | 2020-2025 | Caplyta |
| Lundbeck LLC | $564.79 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $490.76 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $326.63 | 2019-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $229.45 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $193.20 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $123.69 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $103.63 | 2022-2024 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $50.06 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $49.71 | 2022-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $17.32 | 2024 | Azstarys |
| Acadia Pharmaceuticals INC | $16.01 | 2023 | Nuplazid |
| Collegium Pharmaceutical, INC. | $15.77 | 2025 | Jornay Pm |
| Tris Pharma INC | $15.52 | 2025 | |
| Supernus Pharmaceuticals, INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lassise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.